Published in Arch Virol Suppl on January 01, 2001
Herpesvirus assembly and egress. J Virol (2002) 6.39
Physical interaction between envelope glycoproteins E and M of pseudorabies virus and the major tegument protein UL49. J Virol (2002) 2.19
Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A (2005) 1.89
Envelopment of human cytomegalovirus occurs by budding into Golgi-derived vacuole compartments positive for gB, Rab 3, trans-golgi network 46, and mannosidase II. J Virol (2003) 1.80
Binding partners for the UL11 tegument protein of herpes simplex virus type 1. J Virol (2003) 1.64
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48
Deletion of the herpes simplex virus VP22-encoding gene (UL49) alters the expression, localization, and virion incorporation of ICP0. J Virol (2005) 1.47
Array analysis of viral gene transcription during lytic infection of cells in tissue culture with Varicella-Zoster virus. J Virol (2003) 1.44
Conserved herpesvirus protein kinases. Biochim Biophys Acta (2007) 1.17
Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol (2008) 1.15
Varicella-zoster virus open reading frame 66 protein kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells. J Virol (2008) 0.97
The varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator. J Virol (2006) 0.96
Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. J Virol (2006) 0.91
The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS One (2011) 0.89
The varicella-zoster virus immediate-early 63 protein affects chromatin-controlled gene transcription in a cell-type dependent manner. BMC Mol Biol (2007) 0.83
ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection. J Virol (2013) 0.78
ORF9p phosphorylation by ORF47p is crucial for the formation and egress of varicella-zoster virus viral particles. J Virol (2012) 0.78
Molecular genetics of herpes simplex virus. II. Mapping of the major viral glycoproteins and of the genetic loci specifying the social behavior of infected cells. J Virol (1979) 8.05
Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc Natl Acad Sci U S A (1978) 4.31
Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of acanthamoebae from humans with keratitis and from sewage sludge. J Clin Microbiol (2001) 3.98
Occupational therapy for independent-living older adults. A randomized controlled trial. JAMA (1997) 3.47
Herpes simplex virus proteins: DNA-binding proteins in infected cells and in the virus structure. Virology (1975) 3.41
Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience (2002) 3.22
Mutants of herpes simplex virus types 1 and 2 that are resistant to phosphonoacetic acid induce altered DNA polymerase activities in infected cells. J Gen Virol (1976) 3.21
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Altered properties of deoxyribonucleic acid nucleotidyltransferase after infection of mammalian cells with herpes simplex virus. Nature (1966) 2.61
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Genetic and biochemical studies with herpesvirus. Cold Spring Harb Symp Quant Biol (1975) 2.47
Structure of varicella-zoster virus DNA. J Virol (1981) 2.43
Chlorhexidine or polyhexamethylene biguanide for acanthamoeba keratitis. Lancet (1995) 2.36
Coding strategy of the S genome segment of Hantaan virus. Virology (1986) 2.36
Partner's influence on patient preference for treatment in early prostate cancer. BJU Int (2003) 2.33
Gastric intramural pH as a predictor of success or failure in weaning patients from mechanical ventilation. Ann Intern Med (1993) 2.29
Role of cytoplasmic vacuoles in varicella-zoster virus glycoprotein trafficking and virion envelopment. J Virol (1988) 2.22
An approach to evolutionary relationships of mammalian DNA viruses through analysis of the pattern of nearest neighbor base sequences. Cold Spring Harb Symp Quant Biol (1966) 2.20
Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect Immun (1978) 2.15
Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J Virol (1997) 2.14
Regulation of varicella-zoster virus gene expression in human T lymphocytes. J Virol (1992) 2.12
Acanthamoeba griffini. Molecular characterization of a new corneal pathogen. Invest Ophthalmol Vis Sci (1996) 2.09
Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties. J Virol (1985) 2.09
Primary Epstein-Barr-virus infections in acute neurologic diseases. N Engl J Med (1975) 2.02
Comparison of chlorine and chlorine dioxide disinfection for control of Legionella in a hospital potable water supply. J Hosp Infect (1996) 2.01
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
Molecular genetics of herpes simplex virus. III. Fine mapping of a genetic locus determining resistance to phosphonoacetate by two methods of marker transfer. J Virol (1979) 1.97
Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun (1983) 1.95
Non-acanthamoeba amoebic keratitis. J Infect (1997) 1.92
Interaction with nucleic acids and stimulation of the viral DNA polymerase by the herpes simplex virus type 1 major DNA-binding protein. J Virol (1984) 1.91
Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. J Virol (1995) 1.89
Studies on sRNA coded by herpes virus. Cold Spring Harb Symp Quant Biol (1966) 1.85
Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol (1992) 1.81
On the structure, functional equivalence, and replication of the four arrangements of herpes simplex virus DNA. Cold Spring Harb Symp Quant Biol (1979) 1.80
Properties of herpesvirus-induced "immediate early" polypeptides. Virology (1980) 1.75
Molecular genetics of herpes simplex virus: the terminal a sequences of the L and S components are obligatorily identical and constitute a part of a structural gene mapping predominantly in the S component. Proc Natl Acad Sci U S A (1979) 1.73
The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus. Virology (1980) 1.72
Hexavalent capsomers of herpes simplex virus type 2: symmetry, shape, dimensions, and oligomeric status. J Virol (1986) 1.72
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology (1995) 1.72
Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics (1981) 1.69
The varicella-zoster virus immediate early protein, IE62, can positively regulate its cognate promoter. Virology (1992) 1.69
Hantaan virus infection of human endothelial cells. J Virol (1992) 1.65
Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. J Pediatr (2005) 1.64
Evidence that a new enterotoxin of Escherichia coli which activates adenylate cyclase in eucaryotic target cells is not plasmid mediated. Infect Immun (1983) 1.64
Cell-free varicella-zoster virus in cultured human melanoma cells. J Gen Virol (1979) 1.64
Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor. J Virol (1998) 1.62
The major herpes simplex virus DNA-binding protein holds single-stranded DNA in an extended configuration. J Virol (1983) 1.61
Molecular cloning and physical mapping of varicella-zoster virus DNA. Proc Natl Acad Sci U S A (1982) 1.60
New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol (1986) 1.59
A major transactivator of varicella-zoster virus, the immediate-early protein IE62, contains a potent N-terminal activation domain. J Virol (1993) 1.59
Genome differences among varicella-zoster virus isolates. J Gen Virol (1983) 1.59
Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J Virol (1993) 1.58
Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J (1990) 1.53
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol (2006) 1.53
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Osteopenia in children surviving brain tumours. Eur J Cancer (1998) 1.52
Retention of the herpes simplex virus type 1 (HSV-1) UL37 protein on single-stranded DNA columns requires the HSV-1 ICP8 protein. J Virol (1994) 1.52
Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology (2001) 1.50
Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol (1997) 1.50
Site-directed mutagenesis of herpesvirus glycoprotein phosphorylation sites by recombination polymerase chain reaction. PCR Methods Appl (1992) 1.49
Varicella-zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein. Virology (1984) 1.49
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Serine protein kinase associated with varicella-zoster virus ORF 47. Virology (1992) 1.48
Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology (1994) 1.46
Transcription mapping of the varicella-zoster virus genome. J Virol (1985) 1.44
Pyomyositis in an adolescent female athlete. J Pediatr Surg (1995) 1.43
Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis (1979) 1.40
Pharmacoeconomic guidelines: where do we go from here? Value Health (2001) 1.40
Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J Virol (1993) 1.40
Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology (2006) 1.39
Methylation of herpes-simplex-virus deoxyribonucleic acid. Biochem J (1969) 1.39
Herpesvirus proteins: DNA polymerase and pyrimidine deoxynucleoside kinase activities in temperature-sensitive mutants of herpes simplex virus type 2. J Gen Virol (1976) 1.39
Common expression of varicella-zoster viral glycoprotein antigens in vitro and in chickenpox and zoster vesicles. J Infect Dis (1983) 1.39
Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol (2001) 1.37
Human immunodeficiency virus antibodies in sera of Australian blood donors: 1985-1990. Med J Aust (1991) 1.37
Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol (1991) 1.37
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology (1993) 1.36
Acanthamoeba and contact lens disinfection: should chlorine be discontinued? Br J Ophthalmol (1993) 1.36
Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology (1998) 1.35
Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide. J Virol (1988) 1.35
Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol (1988) 1.32
Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base-pair repeat sequence has homology to herpes simplex virus glycoprotein C. J Virol (1986) 1.31
Drainage of CSF through lymphatic pathways and arachnoid villi in sheep: measurement of 125I-albumin clearance. Neuropathol Appl Neurobiol (1996) 1.30
Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. J Virol (2001) 1.29
Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology (1990) 1.29
Embedding health-promoting changes into the daily lives of independent-living older adults: long-term follow-up of occupational therapy intervention. J Gerontol B Psychol Sci Soc Sci (2001) 1.26
Expression of herpes simplex virus type 1 DNA polymerase in Saccharomyces cerevisiae and detection of virus-specific enzyme activity in cell-free lysates. J Virol (1988) 1.25